Korsch

AustinPx Invests in Pharmaceutics and Manufacturing Capabilities to Accelerate Drug Development

Retrieved on: 
Monday, April 8, 2024
Health, Manufacturing, Health Technology, Clinical Trials, Other Manufacturing, Pharmaceutical, Biotechnology, CDMO, Growth, Capsule, Risk, Rheometer, Acquisition, FT4, Senior, Investment, Clinical trial, API, Korsch, Fine chemical

The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.

Key Points: 
  • The latest investments enhance AustinPx’s early phase development and manufacturing capabilities by enabling faster timelines, improved stability, and reduced risk.
  • The technology enables rapid transition into first-in-human clinical trial material manufacturing, while also reducing the cost of drug product development.
  • “These tools enable scientists and engineers to rapidly develop life-changing therapies with enhanced data and quality.”
    The expanded capabilities are now available for use.
  • The additional capabilities mark another milestone in the growth of AustinPx’s formulation development and manufacturing offerings, as the Company continues to position itself as a leading CDMO in the pharmaceutical industry.

DGAP-News: Absence of CEO Hermann J. Merkens, due to ill health, continues

Retrieved on: 
Friday, March 12, 2021
Aareal Bank, Merkens, Korsch, Financial services

Absence of CEO Hermann J. Merkens, due to ill health, continues

Key Points: 
  • Absence of CEO Hermann J. Merkens, due to ill health, continues
    The issuer is solely responsible for the content of this announcement.
  • Absence of CEO Hermann J. Merkens, due to ill health, continues
    Wiesbaden, 12 March 2021 - Today, the Chairman of the Management Board of Aareal Bank AG, Hermann J. Merkens, informed the Chairman of the Supervisory Board, Marija Korsch, that his absence due to ill health will last longer than originally expected and communicated on 8 November 2020.
  • Whether and when Mr Merkens will be able to return to his duties cannot be reliably predicted at this point.
  • The substitution regulations communicated for the Company's Management Board will remain in force until further notice.